Home Lab Testing and Longevity Clinic Panels

What this page covers

Longevity clinics and online services sell blood panels, sometimes ordered from home, that promise to reveal how well you are aging. This page looks at what regulators and researchers say about these tests as a group. It does not name companies, rank services, interpret anyone's numbers, or advise anyone to buy or skip a test. Evidence labels used: established, promising but limited, mixed, insufficient evidence, no good evidence of benefit and marketing claim.

Three questions that decide whether a test is useful

The FDA describes how it judges tests on two of these points. [1]

1. Analytical validity: does the test accurately and reliably measure what it claims to measure? [1]
2. Clinical validity: is the measurement predictive of a certain state of health? [1]
3. Clinical utility: does acting on the result lead to better health than not testing? This is the question most panels have not answered.

A test can pass the first and still fail the third. A precise measurement of a number that nobody has shown to guide better care is not the same as a useful test.

What a 2023 market review found

Researchers in Australia identified 484 direct-to-consumer tests (103 unique products) advertised online and sorted them by potential clinical usefulness. [4]

Potential clinical utility10.7%

Limited clinical utility30.6%

Non-evidence-based commercial "health checks"41.9%

Methods or target conditions not recognized by the medical community16.7%

Of the products, 56% did not state that they offered pretest or post-test consultation, and 51% did not report analytical performance or laboratory accreditation. [4] The authors concluded that most such tests have low potential clinical utility, that healthy consumers are the main target market, and that harms may include overdiagnosis, false positives, treatment decisions based on non-evidence-based tests and cost. [4] This was one country's online market in 2023 and may not describe every service, but the pattern is a useful warning. Label for broad panels as a group: insufficient evidence of benefit.

Does checking many things in healthy people help?

A Cochrane review of 17 randomized trials (251,891 participants in the 15 reporting outcomes) of general health checks in adults not selected for disease found little or no effect on total deaths (risk ratio 1.00) and concluded that general health checks are unlikely to be beneficial. [5] Those trials tested health-check programs, not longevity panels specifically, so this is indirect evidence. Label: no good evidence of benefit for general checks in terms of mortality.

Overtesting and false alarms

Lab results are reported against a reference range based on groups of healthy people, and it is common for healthy people to sometimes have results outside it. [6] The more markers a panel includes, the more chances for a result to fall outside a range for no important reason. Authors discussing wellness testing programs warned about excessive testing leading to overdiagnosis and overtreatment, and questioned the need to "improve" biomarker levels. [7] A biomarker change is not the same as a better health outcome; see Biomarkers and Biological Age Tests.

How to evaluate a panel

• What is each test for, and is there a guideline that supports it in someone like you?
• Does the service describe test accuracy and lab accreditation? In the Australian review about half did not. [4]
• Is a clinician available to explain results and next steps?
• Is the claim about a number, or about living longer or healthier?
• Is there a price per marker, and is a panel of many markers needed for what you want to know?

Related guides

Read Longevity Clinics: What They Offer, Standard Blood Tests and Healthy Aging, Biomarker Tracking and At-Home Tests and Interpreting Test Results Without Overinterpreting. For broad panels sold in integrative practice, see Tests Sold in Integrative Practice.